186 related articles for article (PubMed ID: 29685810)
1. Pulmonary exacerbations and acute declines in lung function in patients with cystic fibrosis.
Wagener JS; Williams MJ; Millar SJ; Morgan WJ; Pasta DJ; Konstan MW
J Cyst Fibros; 2018 Jul; 17(4):496-502. PubMed ID: 29685810
[TBL] [Abstract][Full Text] [Related]
2. Pulmonary exacerbations and clinical outcomes in a longitudinal cohort of infants and preschool children with cystic fibrosis.
Hoppe JE; Wagner BD; Sagel SD; Accurso FJ; Zemanick ET
BMC Pulm Med; 2017 Dec; 17(1):188. PubMed ID: 29228933
[TBL] [Abstract][Full Text] [Related]
3. Lung function changes before and after pulmonary exacerbation antimicrobial treatment in cystic fibrosis.
Wagener JS; VanDevanter DR; Konstan MW; Pasta DJ; Millar SJ; Morgan WJ
Pediatr Pulmonol; 2020 Mar; 55(3):828-834. PubMed ID: 31746561
[TBL] [Abstract][Full Text] [Related]
4. Antibiotic Regimen Changes during Cystic Fibrosis Pediatric Pulmonary Exacerbation Treatment.
Cogen JD; Sanders DB; Slaven JE; Faino AV; Somayaji R; Gibson RL; Hoffman LR; Ren CL
Ann Am Thorac Soc; 2023 Sep; 20(9):1293-1298. PubMed ID: 37327485
[No Abstract] [Full Text] [Related]
5. Predictors of pulmonary exacerbation treatment in cystic fibrosis.
Sanders DB; Ostrenga JS; Rosenfeld M; Fink AK; Schechter MS; Sawicki GS; Flume PA; Morgan WJ
J Cyst Fibros; 2020 May; 19(3):407-414. PubMed ID: 31257102
[TBL] [Abstract][Full Text] [Related]
6. The effect of oral and intravenous antimicrobials on pulmonary exacerbation recovery in cystic fibrosis.
VanDevanter EJ; Heltshe SL; Skalland M; Lechtzin N; Nichols D; Goss CH
J Cyst Fibros; 2021 Nov; 20(6):932-936. PubMed ID: 33685776
[TBL] [Abstract][Full Text] [Related]
7. Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations.
Sanders DB; Solomon GM; Beckett VV; West NE; Daines CL; Heltshe SL; VanDevanter DR; Spahr JE; Gibson RL; Nick JA; Marshall BC; Flume PA; Goss CH;
J Cyst Fibros; 2017 Sep; 16(5):592-599. PubMed ID: 28460885
[TBL] [Abstract][Full Text] [Related]
8. Antibiotic treatment of signs and symptoms of pulmonary exacerbations: a comparison by care site.
Schechter MS; Regelmann WE; Sawicki GS; Rasouliyan L; VanDevanter DR; Rosenfeld M; Pasta D; Morgan W; Konstan MW
Pediatr Pulmonol; 2015 May; 50(5):431-40. PubMed ID: 25530325
[TBL] [Abstract][Full Text] [Related]
9. Characteristics and outcomes of oral antibiotic treated pulmonary exacerbations in children with cystic fibrosis.
Hoppe JE; Wagner BD; Accurso FJ; Zemanick ET; Sagel SD
J Cyst Fibros; 2018 Nov; 17(6):760-768. PubMed ID: 29921503
[TBL] [Abstract][Full Text] [Related]
10. Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV
McColley SA; Konstan MW; Ramsey BW; Stuart Elborn J; Boyle MP; Wainwright CE; Waltz D; Vera-Llonch M; Marigowda G; Jiang JG; Rubin JL
J Cyst Fibros; 2019 Jan; 18(1):94-101. PubMed ID: 30146268
[TBL] [Abstract][Full Text] [Related]
11. Correspondence between lung function and symptom measures from the Cystic Fibrosis Respiratory Symptom Diary-Chronic Respiratory Infection Symptom Score (CFRSD-CRISS).
Gold LS; Patrick DL; Hansen RN; Goss CH; Kessler L
J Cyst Fibros; 2019 Nov; 18(6):886-893. PubMed ID: 31126901
[TBL] [Abstract][Full Text] [Related]
12. Adjunctive Systemic Corticosteroids for Pulmonary Exacerbations of Cystic Fibrosis.
McElvaney OJ; Heltshe SL; Odem-Davis K; West NE; Sanders DB; Fogarty B; VanDevanter DR; Flume PA; Goss CH
Ann Am Thorac Soc; 2024 May; 21(5):716-726. PubMed ID: 38096105
[No Abstract] [Full Text] [Related]
13. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor.
Flume PA; Wainwright CE; Elizabeth Tullis D; Rodriguez S; Niknian M; Higgins M; Davies JC; Wagener JS
J Cyst Fibros; 2018 Jan; 17(1):83-88. PubMed ID: 28651844
[TBL] [Abstract][Full Text] [Related]
14. Evaluating FEV1 decline in diagnosis and management of pulmonary exacerbations in children with cystic fibrosis.
Bouzek DC; Ren CL; Thompson M; Slaven JE; Sanders DB
Pediatr Pulmonol; 2022 Jul; 57(7):1709-1716. PubMed ID: 35429154
[TBL] [Abstract][Full Text] [Related]
15. Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis.
Heltshe SL; Goss CH; Thompson V; Sagel SD; Sanders DB; Marshall BC; Flume PA
Thorax; 2016 Mar; 71(3):223-9. PubMed ID: 25911223
[TBL] [Abstract][Full Text] [Related]
16. Correspondence between symptoms and preference-based health status measures in the STOP study.
Gold LS; Patrick DL; Hansen RN; Beckett V; Goss CH; Kessler L
J Cyst Fibros; 2019 Mar; 18(2):251-264. PubMed ID: 30170756
[TBL] [Abstract][Full Text] [Related]
17. Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations.
West NE; Beckett VV; Jain R; Sanders DB; Nick JA; Heltshe SL; Dasenbrook EC; VanDevanter DR; Solomon GM; Goss CH; Flume PA;
J Cyst Fibros; 2017 Sep; 16(5):600-606. PubMed ID: 28457954
[TBL] [Abstract][Full Text] [Related]
18. BEAT CF pulmonary exacerbations core protocol for evaluating the management of pulmonary exacerbations in people with cystic fibrosis.
Schultz A; McLeod C; Berry S; Marsh J; McKenzie A; Messer M; Wood J; Saville B; Jaffe A; Ranganathan S; Stick S; Wark P; Webb S; Snelling T
Trials; 2023 Mar; 24(1):211. PubMed ID: 36949472
[TBL] [Abstract][Full Text] [Related]
19. Association of Inhaled Antibiotics in Addition to Standard Intravenous Therapy and Outcomes of Pediatric Inpatient Pulmonary Exacerbations.
Cogen JD; Faino AV; Onchiri F; Hoffman LR; Kronman MP; Nelson M; Nichols DP; Rosenfeld M; VanDevanter DR; Gibson RL
Ann Am Thorac Soc; 2020 Dec; 17(12):1590-1598. PubMed ID: 32726564
[No Abstract] [Full Text] [Related]
20. IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosis.
VanDevanter DR; Morris NJ; Konstan MW
J Cyst Fibros; 2016 May; 15(3):372-9. PubMed ID: 26603642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
